Among the least-discussed consequences of the current US regulatory environment for nicotine products is its effect on independent retailers and small businesses in the distribution chain. The compliance costs associated with FDA’s premarket tobacco product application process, the legal uncertainty created by ongoing enforcement actions, and the patchwork of local regulations that apply in addition to federal requirements create a burden that falls disproportionately on smaller players while large multinationals can absorb the costs as a competitive moat.
The PMTA process is the most significant structural barrier. A full application for a nicotine product costs hundreds of thousands of dollars to prepare and requires scientific and regulatory expertise that most small companies cannot maintain in-house. The result is a regulatory framework that effectively requires scale to navigate — large tobacco companies and well-funded independent brands can play, while genuine small businesses cannot. This is not an accident of the regulatory design; it is a predictable consequence of compliance cost structures that were calibrated to the resources of major industry players.
Independent vape shops and specialist nicotine retailers have been particularly hard hit. These businesses invested in product expertise, built customer relationships around harm reduction advice, and developed an economic model around serving adult smokers who wanted to switch. The regulatory environment has been progressively eliminating the products they can legally sell, forcing them to either absorb compliance costs they cannot afford or exit the market.
The irony is that these small businesses often provide a quality of harm reduction support — personal advice, product knowledge, customer relationships — that the large retail chains that survive regulatory consolidation cannot replicate. When the specialist vape shop is replaced by a convenience store that stocks only the products major manufacturers can afford to keep compliant, the harm reduction function is degraded even if the legal product landscape technically satisfies regulatory requirements.
This is an argument that deserves to be made more loudly in regulatory processes that currently hear primarily from large manufacturers and public health advocates. The small business perspective on nicotine regulation represents a legitimate interest that the current framework inadequately accounts for.
